title: Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients.
abstract: BACKGROUND
  Although most studies have not demonstrated decreased patient or graft survival in kidney-alone allograft recipients infected with hepatitis C virus (HCV), the impact of HCV infection on patient and graft survival in HCV-infected kidney-pancreas recipients has not been studied.
  
  
  METHODS
  We undertook a retrospective cohort analysis of 137 kidney-pancreas transplant recipients who were transplanted between January 1989 and May 1996. HCV infection was determined by a positive polymerase chain reaction. Relative risk of death and graft failure was calculated using the Cox proportional hazards model with time-dependent covariates. Relative risks were adjusted (aRR) to control for the number of OKT3-treated rejections and cytomegalovirus status of the recipient at the time of transplantation.
  
  
  RESULTS
  Mean length of follow-up was 30.4 months in the HCV-infected patients compared with 31.7 months in noninfected patients. Seven (5.1%) patients were infected with HCV before transplant, one (1%) relapsed after transplantation, and four (2.9%) acquired the infection after transplantation. The HCV-infected group had a 3.7-fold (95% confidence interval [CI], 1.0-13.5) increased risk of death after transplant compared with the HCV-negative group, with an aRR of 5.5 (95% CI, 1.5-20.0). Death in the HCV-infected group (n=3) was generally the result of liver failure and sepsis, whereas death for those in the uninfected group (n=11) was primarily of cardiovascular origin. Patients infected with HCV were 3.4-fold (95% CI, 1.1-10.1) more likely to develop kidney graft failure than HCV-negative patients with an aRR of 5.1 (95% CI, 1.7-15.4). The risk of pancreatic allograft failure was not significantly increased.
  
  
  CONCLUSIONS
  We conclude that HCV infection in kidney-pancreas transplant patients results in a significantly increased risk of kidney allograft failure and death.
authors.affiliation: Department of Medicine, University of Washington, Seattle 98195, USA.
authors.forename: C O
authors.initials: CO
authors.lastname: Stehman-Breen
authors.forename: B M
authors.initials: BM
authors.lastname: Psaty
authors.forename: S
authors.initials: S
authors.lastname: Emerson
authors.forename: D
authors.initials: D
authors.lastname: Gretch
authors.forename: M
authors.initials: M
authors.lastname: Bronner
authors.forename: C
authors.initials: C
authors.lastname: Marsh
authors.forename: C L
authors.initials: CL
authors.lastname: Davis
mesh_terms: D000328:Adult; D001706:Biopsy; D015331:Cohort Studies; D005260:Female; D006085:Graft Survival / Q000502:physiology; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000473:pathology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology* / Q000401:mortality; D008099:Liver / Q000473:pathology; D008297:Male; D016035:Pancreas Transplantation / Q000009:adverse effects* / Q000276:immunology* / Q000401:mortality; D012333:RNA, Messenger / Q000097:blood; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous / Q000401:mortality
chemical_list: D012333:RNA, Messenger